A RANDOMIZED COMPARATIVE STUDY OF EFFICACY AND SAFETY OF EPALRESTAT AND METHYLCOBALAMIN IN PATIENTS WITH DIABETIC NEUROPATHY

Dr. C. Preeth, Prof. P. Jacob Verghese, Dr. J. Nandhakumar

Abstract


INTORDUCTION: Diabetic neuropathy is a common complication in nearly 50% of over all diabetes population.
Recently Epalrestat and Methylcobalamin are widely used in clinical practice to manage diabetic neuropathy. This study
was aimed to compare the efcacy and safety of Epalrestat and Methylcobalamin in patients with diabetic neuropathy.
METHODS: A total number of 110 patients with diabetic neuropathy were divided into two groups; group A administered with 150 mg of
Epalrestat and group B administered with 1500 mcg of Methylcobalamin once daily basis. The treatment period was 12 weeks with monitoring on
week 4, 8 & 12 of the study. At base line and at follow up visits parameters like pain intensity by VAS pain score, loss of sensation, burning
sensation, numbness, muscle cramps, spontaneous pain, weakness, dizziness, loss of sensation of heat & cold assessed by MNSI & HbA1C.
RESULTS: A signicant improvement in all the efcacy parameters was observed with Epalrestat treatment compared to methylcobalamin
treatment. Epalrestat treatment is associated with very few adverse events. Patients as well as physicians reported that the Epalrestat treatment is
better-quality in efcacy and safety parameters compared to Methylcobalamin.
CONCLUSION: The present study concludes that Epalrestat has superior efcacy and safety prole than Methylcobalamin in the treatment of
diabetic neuropathy.


Keywords


Epalrestat, Methylcobalamin, Mnsi & Diabetic Neuropathy

Full Text:

PDF

References


Keecia DK, Jocelyn DJ, Jessica W. Micro vascular and macro vascular complications of diabetes mellitus. Am J Pharm Educ. 2005; 69: 1-8.

Peeraer, E., Van Lutsenborg, A., Verheyen, A., De Jongh, R., Nuydens, R. and Meert, T.F. Pharmacological evaluation of rat dorsal root ganglion neurons as an in -vitro model for diabetic neuropathy. J Pain Res. 2011; 4, 55-65.

Ramachandran, A., Snehalatha, C., Vijay, V. and Vishwanathan, M. Diabetic retinopathy at the time of diagnosis of NIDDM in South Indian subjects. Diabetes Res Clin Prac. 1996; 32, 111-114.

Chihiro, Y.N. Aldose reductase in glucose toxicity: A potential target for the prevention of diabetic complications. Pharmacological Reviews. 1998; 50, 21-33.

Itagaki, I., Shimizu, K., Kamanaka, Y., Ebata, K., Kik-kawa, R., Haneda, M. and Shigeta, Y. The effect of an aldose reductase inhibitor (epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Prac. 1994; 25, 147-154.

Hotta, N., Kakuta, H., Koh, N., Fukasawa, H., Yasuma, T., Awaya, S. and Sakamoto, N. In- vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor. Diabetes Res Clin Prac.1991;14, 29-35.

Ramirez, M.A. and Borja, N.L. Epalrestat: An al- dose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy. 2008; 28, 646-655.

Sharma, S.R. and Sharma, N. Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective. Ann Indian Acad Neurol. 2008; 11, 231- 235.

Yaqub, B.A., Siddique, A. and Sulimani, R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg. 1992; 94, 105-111.

Sun, Y., Lai, M.S. and Lu, C.J. Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurologica Taiwanica, 2005; 14, 48-54.

Ramirez MA and Boria NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008; 28: 646-55.

Dyck PJ, Karnes J, O'Brien PC, Swanson CJ. Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology. 1986;36:1300-8.

Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg. 1992; 94(2):105-11.

Sun Y, Lai M.S and Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurologica Taiwanica, 2005; 14: 48-54.

Itagaki I, Shimizu K, Kamanaka Y, Ebata K, et al., The effect of an aldose reductase inhibitor (epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Prac. 1994; 25:147-154.

Hotta N, Kakuta H, Koh N, Fukasawa H, et al., In-vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor. Diabetes Res Clin Prac. 1991; 14 : 29-35.

Borghini I, Ania LA, Regazzi R, et al., Alpha, beta II,delta and epsilon protein kinase C isoforms and compound activity in the sciatic nerve of normal and diabetic rats. J Neurochem. 1994; 62: 686-96.

Hempel A, Maasch C, Heintze U, et al., High glucose concentration increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res. 1997;81:363-71.

Mara L. The Polyol Pathway as a Mechanism for Diabetic Retinopathy: Attractive, Elusive, and Resilient. Exp Diabetes Res. 2007, 1-31.


Refbacks

  • There are currently no refbacks.